NCT00313092

Brief Summary

The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2005

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2005

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

April 10, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 11, 2006

Completed
Last Updated

October 2, 2015

Status Verified

October 1, 2015

Enrollment Period

8 months

First QC Date

April 10, 2006

Last Update Submit

October 1, 2015

Conditions

Obstructive Sleep Apnea SyndromeGlaucoma

Keywords

OSASglaucomaMMP

Interventions

nCPAP treatmentDEVICE

treatment with positive air pressure during night

Eligibility Criteria

Age18 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with sleep apnoe syndrom

You may qualify if:

  • OSAS planned begin of a nCPAP treatment

You may not qualify if:

  • Current malignancy
  • Oral steroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Basel, Eye Clinic

Basel, Canton of Basel-City, 4031, Switzerland

Location

Biospecimen

Retention: NONE RETAINED

plasma

MeSH Terms

Conditions

Sleep Apnea, ObstructiveGlaucoma

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesOcular HypertensionEye Diseases

Study Officials

  • Selim Orgül, MD

    University Eye Clinic Basel

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

April 10, 2006

First Posted

April 11, 2006

Study Start

January 1, 2005

Primary Completion

September 1, 2005

Study Completion

September 1, 2005

Last Updated

October 2, 2015

Record last verified: 2015-10

Locations

CH(1)